Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients

NCT02245217 | Completed Results DMC

• 1 other identifier: HCI74163
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

Study of multi-tracer PET scans to assess response to gemcitabine in pancreatic cancer

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (3)

• FDG Therapeutic Responses to 1 Cycle

  The patients underwent baseline and repeat PET/CT imaging (after one cycle) with fluorodeoxyglucose (FDG) and fluorothymidine (FLT). The percent change in the SUVmax for FDG was determined. From these percent change determinations, a response determination was obtained based on the EORTC criteria. EORTC response criteria define a response as \>25% reduction in SUVmax.

  1 month

• FLT Therapeutic Responses to 1 Cycle

  The patients underwent baseline and repeat PET/CT imaging (after one cycle) with FDG and FLT. The percent change in the SUVmax for FLT was determined. From these percent change determinations, a response determination was obtained based on the EORTC criteria. EORTC response criteria define a response as \>25% reduction in SUVmax.

  1 month

• RECIST 1.1 Therapeutic Responses to 1 Cycle

  The patients underwent baseline and repeat PET/CT imaging (after one cycle) with FDG and FLT. Tumor response was determined by RECIST 1.1 and defined as a \>30% reduction in tumor size as determined by the sum of the longest diameters of each index lesion

  1 month

Study Arms (1)

PET/CT Imaging arm

EXPERIMENTAL

Device: PET/CT scan to assess treatment efficacy

Interventions

PET/CT scan to assess treatment efficacy DEVICE

PET/CT Imaging arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have either
• histologically/cytologically-confirmed borderline resectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care
• histologically/cytologically-confirmed locally advanced unresectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care.
• Diagnostic quality abdominal imaging (CT or MRI) within the past 45 days.
• Patients must be willing to lie flat on their back in the PET/CT scanner for up to 2 hours to allow the imaging data to be obtained.
• Patients must document their willingness to be followed for up to 24 months following enrollment in this imaging trial. By signing informed consent, the patients will document their agreement to have clinical and radiographic endpoints and the results of histopathologic tissue analysis and other laboratory information entered into a research database.
• All patients must sign a written informed consent and HIPAA authorization in accordance with institutional guidelines.
• Determination of pregnancy status: Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans. The serum pregnancy test must be performed within 48 hours prior to research PET imaging. A negative test will be necessary for such patients to undergo research PET imaging.
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
• Adequate organ function and laboratory parameters as defined laboratory testing.

You may not qualify if:

• Any prior systemic or investigational therapy for pancreatic cancer.
• Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals (patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion).
• Patients who are pregnant or lactating or who suspect they might be pregnant. - Serum pregnancy tests will be obtained prior to the baseline and subsequent multi-tracer PET scans in female patients that are not postmenopausal or surgically sterile.
• Adult patients who require monitored anesthesia for PET scanning.
• Patients known to be HIV positive. This is due to the potential toxicities of \[18F\]FLT in HIV positive patients.
• Pre-existing sensory neuropathy greater than grade 1.
• Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer or any other form of cancer from which the patient has been disease-free for 5 years.
• Uncontrolled diabetes or blood glucose greater than 180 mg/dl on the day of the \[18F\] fluorodeoxyglucose (FDG) PET scan.
• Major surgery within 4 weeks of the start of study treatment, without complete recovery.
• Any other condition that would, in the Investigator's judgment, contraindicate patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g. infection/inflammation, intestinal obstruction, social complications.

Sponsors & Collaborators

• University of Utah: lead

Study Sites (1)

Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Results Point of Contact

• Title: Josiah Hawks
• Organization: Huntsman Cancer Institute

Josiah.Hawks@hci.utah.edu

8015850601

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2014
• First Posted: September 19, 2014
• Study Start: December 12, 2014
• Primary Completion: March 17, 2016
• Study Completion: March 17, 2016
• Last Updated: October 15, 2021
• Results First Posted: March 8, 2018

Record last verified: 2021-09

Locations

US (1)